(1) Maksymiuk AW, Jett JR, Earle JD, Su JQ, Diegert FA, Mailliard JA et al. Sequencing and schedule effects of cisplatin plus etoposide in small- cell lung cancer: results of a North Central Cancer Treatment Group randomized clinical trial. J Clin Oncol 1994; 12(1):70-76.
(2) Sundstrom S, Bremnes RM, Kaasa S, Aasebo U, Hatlevoll R, Dahle R et al. Cisplatin and Etoposide Regimen Is Superior to Cyclophosphamide, Epirubicin, and Vincristine Regimen in Small-Cell Lung Cancer: Results From a Randomized Phase III Trial With 5 Years' Follow-Up. J Clin Oncol 2002; 20(24):4665-4672.
(3) Thatcher N, Qian W, Clark PI, Hopwood P, Sambrook RJ, Owens R et al. Ifosfamide, carboplatin, and etoposide with midcycle vincristine versus standard chemotherapy in patients with small-cell lung cancer and good performance status: clinical and quality-of-life results of the British Medical Research Council multicenter randomized LU21 trial. J Clin Oncol 2005; 23(33):8371-8379.
(4) Baka S, Califano R, Ferraldeschi R, Aschroft L, Thatcher N, Taylor P, et al. Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer. Br J Cancer 2008 Aug 5;99(3):442-7.